A group of scientists has claimed to have discovered “more magnificent chemotherapy” that can target cancer cells more accurately than existing treatments affecting the surrounding areas of those cells.
The technology, based on DNA editing technology, has already been used in mice and could be used on humans in the next two years, scientists said.
Professor Dan Pierre, a cancer specialist at Tel Aviv University in Israel, explained that there were no “side effects” and that he believed that “cancer cells treated in this way would never reactivate.” Times of Israel.
“This technology can prolong the life of cancer patients and we hope that, one day, cure this disease.”
The study, published by scientists at Tel Aviv University, New York University and Harvard Medical School, was published in the journal Science progress.
Scientists claim that for the first time in the world, the Crisper genome editing technology, which works by cutting out a portion of DNA, has been used effectively to treat cancer in animals.
Professor Pierre explained that if this technique was used, within three treatments, “we can destroy the tumor” because it could “physically cut the DNA into cancerous cells, and those cells would not survive.”
He acknowledged that the technology needed to be “further developed”, but said that the main point of the current study was that it showed that it could “kill cancer cells”.
Scientists found that rats with cancer that had been treated had doubled their lifespan and had a 30 percent higher survival rate than those in the control group.
Professor Pierre revealed that once adapted to humans, the treatment can be made very individual and customizable for each patient, whether given as a simple injection or a direct tumor injection.
For the study, researchers focused on two cancers from malignant cancers – metastatic ovarian cancer and gyloblast last ma, an invasive type of brain cancer. In globlastoma, life expectancy and survival rates are usually very low.
But, according to the study, injections against glioblastoma “increased tumor growth by 50%” and “improved survival by 0%” while in the case of ovarian tumors it “increased by 0%.
“The ability to disrupt gene expression in vivo in tumors opens up new avenues for cancer treatment and research and potential applications for target gene acquisition of non-aneurysm tissue,” the study said.
